Maemondo, Makoto <br/><br/>
First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.  [electronic resource] 

 -  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer  Sep 2012 
 - 1417-22 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1556-1380 
<br/><br/><label>Standard No.: </label>10.1097/JTO.0b013e318260de8b  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--therapeutic use<br/>Carcinoma, Adenosquamous--drug therapy<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>ErbB Receptors--antagonists & inhibitors<br/>Feasibility Studies<br/>Female<br/>Follow-Up Studies<br/>Gefitinib<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Mutation--genetics<br/>Neoplasm Staging<br/>Prognosis<br/>Quinazolines--therapeutic use<br/>Survival Rate